Page last updated: 2024-09-05

erlotinib hydrochloride and Diabetic Cardiomyopathies

erlotinib hydrochloride has been researched along with Diabetic Cardiomyopathies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Huang, L; Liang, G; Luo, W; Qian, Y; Wang, J; Wang, Y; Xu, Z; Yin, H; Zheng, C; Zhuang, F	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Diabetic Cardiomyopathies

Article	Year
Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes. The Journal of endocrinology, 2019, 09-01, Volume: 242, Issue:3 Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Rats; STAT3 Transcription Factor	2019

Article

Year

Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes.

The Journal of endocrinology, 2019, 09-01, Volume: 242, Issue:3

Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Rats; STAT3 Transcription Factor

2019